Related Experiment Video
Updated: Oct 5, 2025
Author Spotlight: Innovative Cancer Therapies with Iron Oxide Nanoparticles for Glioblastoma Treatment
Published on: September 27, 2024
Betulinic acid self-assembled nanoparticles for effective treatment of glioblastoma
Yong Li1, Yixuan Wang1, Lun Gao1
1Department of Neurosurgery, Renmin Hospital of Wuhan University, Wuhan, Hubei, 430060, People's Republic of China.
Background:
Glioblastoma (GBM) is the most common and fatal primary tumor in the central nervous system (CNS). Due to the existence of blood-brain barrier (BBB), most therapeutics cannot efficiently reach tumors in the brain, and as a result, they are unable to be used for effective GBM treatment. Accumulating evidence shows that delivery of therapeutics in form of nanoparticles (NPs) may allow crossing the BBB for effective GBM treatment.
Methods:
Betulinic acid NPs (BA NPs) were synthesized by the standard emulsion approach and characterized by electron microscopy and dynamic light scattering analysis. The resulting NPs were characterized for their anti-tumor effects by cell viability assay, EdU-DNA synthesis assay, cell cycle assay, mitochondrial membrane potential, and PI-FITC apoptosis assay. Further mechanistic studies were carried out through Western Blot and immunostaining analyses. Finally, we evaluated BA NPs in vivo for their pharmacokinetics and antitumor effects in intracranial xenograft GBM mouse models.
Results:
BA NPs were successfully prepared and formed into rod shape. BA NPs could significantly suppress glioma cell proliferation, induce apoptosis, and arrest the cell cycle in the G0/G1 phase in vitro. Furthermore, BA NPs downregulated the Akt/NFκB-p65 signaling pathway in a concentration dependent manner. We found that the observed anti-tumor effect of BA NPs was dependent on the function of CB1/CB2 receptors. Moreover, in the intracranial GBM xenograft mouse models, BA NPs could effectively cross the BBB and greatly prolong the survival time of the mice.
Conclusions:
We successfully synthesized BA NPs, which could cross the BBB and demonstrated a strong anti-tumor effect. Therefore, BA NPs may potentially be used for effective treatment of GBM.
Insights
Betulinic acid nanoparticles (BA NPs) effectively cross the blood-brain barrier (BBB) to treat glioblastoma (GBM). These BA NPs show significant anti-tumor effects, offering a promising new therapeutic strategy for brain cancer.
Area of Science:
- Nanomedicine
- Oncology
- Neuroscience
Background:
- Glioblastoma (GBM) is a fatal brain tumor with limited treatment options due to the blood-brain barrier (BBB).
- Nanoparticle (NP) delivery systems show potential for overcoming BBB limitations in CNS cancer therapy.
Purpose of the Study:
- To synthesize and characterize Betulinic acid nanoparticles (BA NPs).
- To evaluate the in vitro and in vivo anti-tumor efficacy of BA NPs against GBM.
- To investigate the therapeutic potential of BA NPs for GBM treatment.
Main Methods:
- BA NPs were synthesized via emulsion and characterized using electron microscopy and dynamic light scattering.
- In vitro studies included cell viability, proliferation, cell cycle, mitochondrial potential, and apoptosis assays.
- In vivo studies involved pharmacokinetic analysis and efficacy testing in intracranial GBM xenograft mouse models.
Main Results:
- Rod-shaped BA NPs were successfully prepared and demonstrated significant suppression of glioma cell proliferation and induction of apoptosis in vitro.
- BA NPs downregulated the Akt/NFκB-p65 signaling pathway and their anti-tumor effect was linked to CB1/CB2 receptor function.
- In vivo, BA NPs effectively crossed the BBB and significantly prolonged survival in GBM xenograft mouse models.
Conclusions:
- Synthesized BA NPs exhibit potent anti-tumor activity against GBM.
- BA NPs demonstrate the ability to cross the BBB, a critical factor for brain tumor treatment.
- BA NPs represent a promising therapeutic candidate for effective glioblastoma treatment.
